Evidence map›Paper›PMID 33326871›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease-A report from Central and Eastern Europe.

Justyna D Kowalska, Kerstin Kase, Anna Vassilenko, Arjan Harxhi, Botond Lakatos, Gordana Dragović Lukić, Antonija Verhaz, Nina Yancheva, Florentina Dumitrescu, David Jilich and 3 more

Abstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. HIV and COVID-19: review of clinical course and outcomes.HIV research & clinical practice · 2021
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Justyna D KowalskaDepartment of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Poland. Electronic address: jdkowalska@gmail.com.
Kerstin KaseWest Tallinn Central Hospital, Estonia.
Anna VassilenkoBelarusian State Medical University, Minsk, Belarus.
Arjan HarxhiUniversity Hospital Center of Tirana, Infectious Disease Service, Albania.
Botond LakatosNational Institute of Hematology and Infectious Diseases, South-Pest Central Hospital, National Center of HIV, Hungary.
Gordana Dragović LukićDepartment of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Serbia.
Antonija VerhazClinic for Infectious Diseases, University Clinical Centre of the Republic of Srpska, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina; Department for Infectious Diseases, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia and Herzegovina.
Nina YanchevaDepartment for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Disease Sofia, Bulgaria.
Florentina DumitrescuUniversity of Medicine and Pharmacy Craiova, Romania.
David JilichDepartment of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital, Czech Republic.
Ladislav MachalaDepartment of Infectious Diseases, 3rd Faculty of Medicine, Charles University in Prague and Na BuLovce Hospital, Czech Republic.
Agata Skrzat-KlapaczyńskaDepartment of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Poland.
Raimonda MatulionyteDepartment of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is currently no evidence suggesting that COVID-19 takes a different course in HIV-positive patients on antiretroviral treatment compared to the general population. However, little is known about the relation between specific HIV-related factors and the severity of the COVID-19 disease.

methodsWe performed a retrospective analysis of cases collected through an on-line survey distributed by the Euroguidelines in Central and Eastern Europe Network Group. In statistical analyses characteristics of HIV-positive patients, asymptomatic/moderate and moderate/severe course were compared.

resultsIn total 34 HIV-positive patients diagnosed with COVID-19 were reported by 12 countries (Estonia, Czech Republic, Lithuania, Albania, Belarus, Romania, Serbia, Bosnia and Herzegovina, Poland, Russia, Hungary, Bulgaria). Asymptomatic courses of COVID-19 were reported in four (12%) cases, 11 (32%) patients presented with mild disease not requiring hospitalization, moderate disease with respiratory and/or systemic symptoms was observed in 14 (41%) cases, and severe disease with respiratory failure was found in five (15%) patients. The HIV-related characteristics of patients with an asymptomatic/mild course of COVID-19 were comparable to those with a moderate/severe course of COVID-19, except for the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in cART regimen (0.0% vs. 31.6% respectively, p = 0.0239).

conclusionsIn our analyses HIV viral suppression and immunological status were not associated with the course of COVID-19 disease. On the contrary the cART regimen could contribute to severity of SARS-CoV-2 infection. Large and prospective studies are necessary to further investigate this relationship.

Indexed as

SARS-CoV-2AdultAnti-Retroviral AgentsCOVID-19COVID-19 Drug TreatmentEurope, EasternFemaleHIV InfectionsHumansMaleMiddle AgedProtease InhibitorsRetrospective StudiesSurveys and QuestionnairesAnti-Retroviral AgentsProtease InhibitorsAntiretroviral therapyCOVID-19HIVProtease inhibitorsSARS-CoV-2

Identifiers

PMID33326871
PMCPMC7834141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.